Health Minister Hsueh Jui-yuan (薛瑞元) said Wednesday the ministry's commissioning of Choice Pharma Taiwan to conduct Phase 2 clinical trials of the locally manufactured Medigen COVID-19 vaccine predated a merger between Choice Pharma's parent company and a Shanghai-based firm, amid controversy over possible Chinese involvement in the trials.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Society
Water, tea, energy drink bottles most common beach litter: NGO
07/17/2025 04:35 PM - Business
U.S. dollar closes lower on Taipei forex market
07/17/2025 04:17 PM - Business
CIER forecasts Taiwan's GDP growth at 3.05% for 2025
07/17/2025 04:16 PM - Business
TSMC Q2 net profit hits new high
07/17/2025 03:47 PM - Politics
Han Kuang: Army choppers practice hot-pit refueling in New Taipei, Taichung
07/17/2025 02:47 PM